FROM THE CLINICAL EFFECTIVENESS UNIT (CEU)

The members’ enquiry service: frequently asked questions September 2002–August 2003 and an illustrative CEU response

Alison de Souza, MPH, Research Assistant; Susan Brechin, MRCPG, FFPRHC, Unit Co-ordinator; Gillian Penney, FRCPG, FFPRHC, Honorary Director, Clinical Effectiveness Unit, Faculty of Family Planning and Reproductive Health Care, London, UK

Correspondence: Ms A de Souza: FFPRHC, University of Aberdeen, School of Medicine, University Avenue, Aberdeen AB25 2ZD, UK. Tel +44 (0) 1224 553623. E-mail: fprhc@abdn.ac.uk

(Accepted 6 February 2004)
Journal of Family Planning and Reproductive Health Care 2004; 30(2): 111–113

Introduction

In this article, the Clinical Effectiveness Unit (CEU) provides an overview of the enquiries received in their first year of operation, from September 2002 to August 2003. An illustrative response to one frequently asked question (FAQ), namely the use of progestogen-only emergency contraception (POEC) by women taking liver enzyme-inducers, is given at the end of this overview. All CEU enquiry responses will soon be accessible via a searchable facility on the Faculty of Family Planning and Reproductive Health Care (FFPRHC) website.

By the end of August 2003 the CEU had responded to 300 enquiries. The majority (70%) of these were received by e-mail, 19% by telephone, 10% by post and 1% by fax. Figure 1 summarises the topic areas covered by these enquiries.

The largest category of enquiries, ‘all methods’ (60 enquiries), included questions about contraceptive choices for women with specific clinical conditions or syndromes.

The ‘intrauterine devices’ category included questions on protocols for insertion and removal, efficacy of different devices, and the suitability of this method for women with specific clinical conditions. Questions on testing for Chlamydia trachomatis prior to insertion and on the relevance of actinomyces-like organisms on cervical smears of intrauterine contraceptive device users were answered individually and have also been addressed in the CEU Guidance document ‘The copper intrauterine device as long-term contraception’.1

Within the ‘combined pills’ category, clinicians sought advice on the risks of venous thromboembolism and breast cancer, on different doses of combined oral contraception, and on drug interactions. A common enquiry topic was combined contraceptive use by women taking anti-epileptic liver enzyme-inducers. This topic was covered in a previously published illustrative response.2

The two most common topics within the ‘depot injectables’ category related to ‘late injections’ and to the effects of long-term use on bone mineral density. Our responses on late depot medroxyprogesterone acetate (DMPA) injections were based on guidance in the World Health Organization (WHO) Selected Practice Recommendations for Contraceptive Use.3 A response on the effects of DMPA on bone mineral density has been published as an illustrative FAQ.4

Within the ‘services’ category, members asked for guidance on cervical smears, including the role of the pelvic examination, and accuracy of different screening techniques. Fifteen enquiries related to ‘progestogen-only emergency contraception’. The new, approved regimen of a single 1.5 mg dose taken within 72 hours of unprotected sexual intercourse featured in many responses and in our formal CEU Guidance on ‘Emergency contraception’.5 Several members were unsure about the application of this new regimen for women using liver enzyme-inducers. To clarify this issue, the CEU provides a response to this FAQ here. Enquiry topics on the ‘etongestrel implant’ included duration of use in women with a high body mass index.

The CEU answered multiple enquiries on the following topics: the relationship between hormone replacement therapy and breast cancer; the reliability of gonadotrophin measurements in diagnosis of the menopause; the risk of venous thromboembolism with all forms of progestogen-only contraceptives and with pills containing cyproterone acetate; the risks of the spermicide, nonoxynol-9; and efficacy of the progestogen–only pill in women weighing >70 kg. The CEU has published a response to this latter FAQ.6 Isolated enquiries were received on the CEU Guidance document ‘Contraceptive choices for women with inflammatory bowel disease’.7 On the efficacy of new contraceptive products such as the desogestrel-only pill, and on sterilisation and vasectomy.

The CEU also received 43 miscellaneous queries, which are not included in this summary of the members’ enquiry service. These included requests for information on ongoing clinical trials, new product details, audit standards, medicolegal advice, and access to CEU publications or presentations.

Table 1 summarises the 10 most common topic areas of questions asked during the CEU’s first year in operation. The CEU has provided answers to most of these FAQs in previous illustrative responses or in their Guidance documents.
From the CEU

Population: Literature search strategy
Evidence-based medicine question (which guided our levonorgestrel) 12 hours later. Women should take one additional tablet (0.75 mg contraceptive failure. There is no evidence available to be administered as two tablets taken together (1.5 mg POEC can be administered as two tablets taken together (1.5 mg progestogen-only contraception for women taking liver enzyme-inducers. Follow-up of women using different contraceptives. Testing for Chlamydia trachomatis prior to intrauterine device (IUD) insertion. Relevance of actinomyces-like organisms on cervical smears of women with IUDs or prior to IUD insertion. The risks of venous thromboembolism (VTE) in women using progestogen-only contraception. The risk of VTE in women using pills containing cyproterone acetate.

Illustrative CEU response
Clinical question
For women taking liver enzyme-inducers, what dose of POEC is effective?

Summary of response
The CEU recommends that, in routine practice, POEC can be administered as two tablets taken together (1.5 mg levonorgestrel), which should be taken as soon as possible, and within 72 hours of unprotected sex or potential contraceptive failure. There is no evidence available regarding use of POEC in women using liver enzyme-inducers; currently, a consensus opinion is that such women should take one additional tablet (0.75 mg levonorgestrel) 12 hours later.

Evidence-based medicine question (which guided our literature search strategy)

Information sources
The CEU searched the sources listed in Table 2 in developing this Member’s Enquiry Response.

Evidence reviewed
Existing FFPRHC Guidance. The CEU Guidance on ‘Emergency contraception’ (April 2003) updated previous Faculty Guidance. The dose of POEC should be increased by 50% for women using liver enzyme-inducers. 
Alternatively women should consider using a copper intrauterine device which is unaffected by liver enzyme-inducers. The CEU recommended that for women using liver enzyme-inducers, two tablets (i.e. 1.5 mg) of levonorgestrel should be taken as soon as possible and within 72 hours of unprotected sex. This should be followed by one tablet (0.75 mg) of levonorgestrel 12 hours later. This advice is supported by the Scottish Intercollegiate Guidelines Network in a Guideline on the diagnosis and management of epilepsy in adults, by advice in the current edition of the British National Formulary10 and Guidance from the Department of Health.11 This advice is, however, based on non-analytical studies, expert opinion and data extrapolated from higher quality studies. There are no data on the optimal dose and timing of POEC in women using liver enzyme-inducers.

MEDLINE and EMBASE. A large, randomised, controlled trial, conducted by the WHO12 found that a single 1.5 mg dose of levonorgestrel was equivalent to the divided regimen of 0.75 mg taken 12 hours apart in women not using liver enzyme-inducers. Although equivalence cannot be demonstrated with absolute certainty, these data from the WHO trial provided sufficient evidence to support a change to the product licence for Levonelle® and Levonelle-2® (Schering Health Care). The Medicines and Healthcare products Regulatory Agency granted a change to the product licence in October 2003, which allows POEC to be given as a single 1.5 mg dose in routine practice.13 Although the WHO data supported a single dose (1.5 mg) of levonorgestrel in routine practice, no evidence was identified regarding the use of POEC by women taking liver enzyme-inducers. Currently there is no evidence to support a single regimen of three tablets (i.e. 2.25 mg) of levonorgestrel for women taking liver enzyme-inducers. Although this regimen may seem logical, there is no evidence to support it at this time or to predict the side effects, such as nausea or vomiting, which may occur. Until more evidence is available, the recommendation for POEC use by women taking liver enzyme-inducers has not changed.

Disclaimer
The advice given in this Member’s Enquiry Response has been prepared by the FFPRHC Clinical Effectiveness Unit team. It is based on a structured search and review of published evidence available at the date of preparation. The advice given here should be considered as guidance only. Adherence to it will not ensure a successful outcome in every case and it may not include all acceptable methods of care aimed at the same results. This response has been prepared as a service to FFPRHC members, but is not an official Faculty Guidance product; Faculty Guidance is produced by a different and lengthier process. It is not intended to be construed or to serve as a standard of medical care. Such standards are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge advances. Members are welcome to reproduce this Response by photocopying or other means, in order to share the information with colleagues.

Acknowledgement
The CEU acknowledges the support provided by Mrs Tracey Chiverton, the CEU Secretary responsible for maintaining the CEU Members’ Enquiry Database.

Table 1 The 10 most common themes of members’ enquiries during the period September 2002–August 2003

| 1 | The use of combined oral contraception by women taking anti-epileptic liver enzyme-inducers. |
| 2 | Guidance on late depot medroxyprogesterone acetate (DMPA) injections. |
| 3 | The effects of long-term DMPA use on bone mineral density. |
| 4 | The risk of vaginal ulceration and sexually transmitted infections with condoms lubricated with nonoxynol-9. |
| 5 | Efficacy of the single 1.5 mg dose of progestogen-only emergency contraception for women taking liver enzyme-inducers. |
| 6 | Follow-up of women using different contraceptives. |
| 7 | Testing for Chlamydia trachomatis prior to intrauterine device (IUD) insertion. |
| 8 | Relevance of actinomyces-like organisms on cervical smears of women with IUDs or prior to IUD insertion. |
| 9 | The risks of venous thromboembolism (VTE) in women using progestogen-only contraception. |
| 10 | The risk of VTE in women using pills containing cyproterone acetate. |

Table 2 Sources used in developing the Member’s Enquiry Response

<table>
<thead>
<tr>
<th>Source searched</th>
<th>Information identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Existing FFPRHC and RCOG Guidance</td>
<td>See text</td>
</tr>
<tr>
<td>The National Guidelines Clearing House</td>
<td>See text</td>
</tr>
<tr>
<td>WHO publications: Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use (2000) and Selected Practice Recommendations for Contraceptive Use (2002)</td>
<td>No relevant information</td>
</tr>
<tr>
<td>The Cochrane Library</td>
<td>No relevant information</td>
</tr>
<tr>
<td>MEDLINE and EMBASE from 1996 to 2004</td>
<td>See text</td>
</tr>
</tbody>
</table>

FFPRHC, Faculty of Family Planning and Reproductive Health Care; RCOG, Royal College of Obstetricians and Gynaecologists; WHO, World Health Organization.

References
SHORT COMMUNICATION

The prevalence rates of domestic abuse in women attending a family planning clinic

June Keeling, BSc, RGN, Domestic Violence Co-ordinator/Researcher; Linda Birch, BSc, MA, Senior Lecturer/Practitioner, Duchess of Westminster Wing, Arrowe Park Hospital, Upton, UK

Correspondence: Mrs June Keeling, PDRU, Duchess of Westminster Wing, Arrowe Park Hospital, Arrowe Park Road, Upton, Wirral CH49 5PE, UK. E-mail: june.keeling@whnt.nhs.uk


Objective To examine the prevalence rates of domestic abuse.

Participants Two hundred and ninety-two women.

Main outcome measures The prevalence rate of past and present history of domestic abuse and the nature of the abuse.

Results One in three women experienced domestic abuse at some time in their life. A significant relationship existed between the age of the woman and experiencing abuse within the last year. Women in full-time employment experienced the highest rates of abuse.

Discussion The anonymity of the research and the method of implementation encouraged an excellent response rate.

Conclusion During a woman's childbearing years, one-third of women may experience domestic abuse from their partner.

Method The Wirral Ethics Committee granted ethical approval and the research commenced in May 2002. All women attending the FPC at the district general hospital were invited to participate. There were no exclusions. Any accompanying partner (male or female) was surreptitiously removed to ensure the woman’s and the researcher’s safety. Following verbal consent, a self-administered questionnaire was completed in private to ensure a non-coercive response.

Quantitative data collection was achieved using an anonymous self-administered questionnaire, the Abuse Assessment Screen (AAS).4 The Nursing Research Consortium on Violence and Abuse developed the AAS. It uses five closed questions to assess past and recent history of abuse and the nature of the abuse. The reliability of the AAS has been demonstrated to be equivalent to the Conflict Tactic Scale.5 The AAS was supplemented to enable the collection of demographic data. The right to refuse was upheld and women were assured that this would not alter the care they received. The number of refusals was recorded.

Table 1 Prevalence of domestic abuse by age group

<table>
<thead>
<tr>
<th>Age range (years)</th>
<th>Completed questionnaires (n) (% of total)</th>
<th>Women reporting domestic abuse at some stage in their life (n) (% of each age group)</th>
<th>Women reporting domestic abuse in the last 12 months (n) (% of each age group)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16–24</td>
<td>105 (36.0)</td>
<td>34 (32.4)</td>
<td>24 (22.9)</td>
</tr>
<tr>
<td>25–29</td>
<td>46 (15.8)</td>
<td>14 (30.4)</td>
<td>3 (6.5)</td>
</tr>
<tr>
<td>30–34</td>
<td>47 (16.1)</td>
<td>18 (38.3)</td>
<td>3 (6.4)</td>
</tr>
<tr>
<td>35–39</td>
<td>42 (14.4)</td>
<td>19 (45.2)</td>
<td>6 (14.3)</td>
</tr>
<tr>
<td>40–44</td>
<td>25 (8.6)</td>
<td>6 (24.0)</td>
<td>1 (4)</td>
</tr>
<tr>
<td>45–49</td>
<td>9 (3.1)</td>
<td>5 (55.6)</td>
<td>1 (11.1)</td>
</tr>
<tr>
<td>≥50</td>
<td>11 (3.8)</td>
<td>2 (18.2)</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Missing data</td>
<td>7 (2.4)</td>
<td>4 (57.1)</td>
<td>2 (28.6)</td>
</tr>
<tr>
<td>Totals</td>
<td>292 (100)</td>
<td>102 (34.9)</td>
<td>41 (14.0)</td>
</tr>
</tbody>
</table>

Introduction Domestic abuse can be defined as ‘any violence between current or former partners in an intimate relationship, wherever and whenever the violence occurs’. The violence can include physical, sexual, emotional or financial abuse.1 Sexual violence includes forced anal, oral and vaginal sex and enforced prostitution, which may result in sexual dysfunction.2 The abusive partner may also control the woman’s choice of contraceptive method. A recent study identified that 26.2% of women had experienced partner control over the choice of family planning methods.3 The aim of this research was to identify the prevalence rate of domestic abuse experienced by women accessing a family planning clinic (FPC).

The members’ enquiry service: frequently asked questions September 2002–August 2003 and an illustrative CEU response
Alison de Souza, Susan Brechin and Gillian Penney

*J Fam Plann Reprod Health Care* 2004 30: 111-113
doi: 10.1783/147118904322995492

Updated information and services can be found at:
http://jfprhc.bmj.com/content/30/2/111.citation

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/